From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy

Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges

<p>Self-Assembled Nanoparticles Prepared from Low-Molecular-Weight PEI and Low-Generation PAMAM for EGFRvIII-Chimeric Antigen Receptor Gene Loading and T-Cell Transient Modification</p>